Menu

Experience

Geoffrey Spolyar

    • ERYTECH – $144 Million IPO 


    • ZELTIQ Aesthetics to Sell to Allergan for $2.5 Billion 


    • Cooley Advises on Nightstar + NuCana IPOs 


    • Jazz Pharmaceuticals Acquisition of Redx Pharma's pan-RAF Inhibitor Program Valued up to $206 Million 


    • X4 Pharmaceuticals in its Exclusive License Agreement with Abbisko Therapeutics 


    • GENFIT SA in its Licensing and Collaboration Agreement with Terns Pharmaceuticals 


    • Innate Pharma - $79 Million IPO 


    • Therachon Sells to Pfizer for up to $810 Million 


    • AN2 Therapeutics in its Exclusive License Agreement with Brii Biosciences 


Contact us

Back to top

© 2020 Cooley LLP and Cooley (UK) LLP. All rights reserved.

Cooley® is a registered service mark of Cooley LLP in the United States and European Union as well as certain other jurisdictions.